Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Credit agrmnt [a]
CC transcript
Asset disposition
Acq. announced
Director departure
Appointed COO
Orthofix Medical Inc. (OFIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Investor presentation, Quarterly results
Docs: "Orthofix Reports Second Quarter 2023 Results and Raises Revenue and Adjusted EBITDA Guidance • Net sales of $187.0 million, an increase of 58% on a reported basis and 7% on a pro forma constant currency basis over prior year • Bone Growth Therapies growth of 10%, marking two consecutive quarters with double-digit net sales increases, with growth coming from both spine and fracture commercial channels • U.S. spinal implants, biologics, and enabling technologies sales up 7% over prior year on a pro forma basis, driven by new distribution and product innovation • Global Orthopedics net sales increase of 6% on a reported basis and 5% on a constant currency basis over prior year • Announced full commercial launch of the following products: o WaveForm® A interb...",
"Corporate Investor Deck August 2023 Forward Looking Statements This"
05/24/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Orthofix Reports First Quarter 2023 Results • Net sales of $175.2 million, an increase of 65% on a reported basis and 12% on a pro forma constant currency basis over prior year • Bone Growth Therapies growth of 14%, with growth coming from both spine and fracture commercial channels • U.S. spinal implant sales up 18% over prior year on a pro forma basis, driven by new distribution and product innovation • Continued double-digit growth in Global Orthopedics over prior year on a constant currency basis • Announced the full commercial launch of the Lattus™ Lateral Access System and the Fathom™ Pedicle-Based Retractor System, which addresses an estimated $1.8 billion market related to minimally invasive spine procedures"
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/06/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Quarterly results
Docs: "Orthofix Medical Reports Orthofix and SeaSpine Fourth Quarter and Full-Year 2022 Results LEWISVILLE, Texas — March 6, 2023 — The merger of Orthofix Medical Inc. and SeaSpine Holdings Corporation became effective as of January 5, 2023. This news release includes the financial results of stand-alone Orthofix and stand-alone SeaSpine for the fourth quarter and full year ended December 31, 2022. As such, these financial results do not include any potential accounting adjustments the merger may have on future net sales or operating results. Orthofix Fourth Quarter Highlights • Net sales of $122.2 million, a decrease of 2% on a reported basis and flat on a constant currency basis over prior year • Bone Growth Therapies net sales growth of approximately 3%, driven by the commercial ..."
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 7.1% stake in Orthofix Medical Inc.
01/11/2023 5 West Thomas A. (Director) has filed a Form 5 on Orthofix Medical Inc.
01/11/2023 5 MARKS LILLY (Director) has filed a Form 5 on Orthofix Medical Inc.
01/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Orthofix Medical Inc. Announces Preliminary SeaSpine and Orthofix 2022 Fourth Quarter and Full-Year Net Sales Results LEWISVILLE, Texas — January 9, 2023 — The merger of equals between Orthofix Medical Inc. and SeaSpine Holdings Corporation became effective as of January 5, 2023. This news release includes the pre-merger unaudited preliminary net sales results of stand-alone SeaSpine and stand-alone Orthofix for the fourth quarter and full year ended December 31, 2022. As such, these preliminary financial results do not include any potential accounting adjustments that the merger may have on future net sales results. SeaSpine Fourth Quarter Highlights • Net sales of $63.2 - $63.7 million, an increase of more than 13% on a reported basis over prior year and an increase of more than 1..."
01/05/2023 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Fina...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Form of Indemnification Agreement between Orthofix Medical Inc. and its directors and officers",
"Offer Letter between the Company and Keith C. Valentine",
"Offer Letter between the Company and John J. Bostjancic",
"Offer Letter between the Company and Patrick L. Keran",
"Orthofix and SeaSpine Announce Completion of Merger of Equals to Create a Leading Global Spine and Orthopedics Company"
01/04/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
01/04/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
12/27/2022 425 Form 425 - Prospectuses and communications, business combinations:
12/27/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
12/05/2022 425 Form 425 - Prospectuses and communications, business combinations:
12/05/2022 8-K Quarterly results
11/30/2022 425 Form 425 - Prospectuses and communications, business combinations:
11/30/2022 8-K Quarterly results
11/23/2022 EFFECT Form EFFECT - Notice of Effectiveness:
11/22/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
11/22/2022 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
11/18/2022 425 Form 425 - Prospectuses and communications, business combinations:
11/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing"
11/18/2022 425 Form 425 - Prospectuses and communications, business combinations:
11/17/2022 425 Form 425 - Prospectuses and communications, business combinations:
11/08/2022 S-4 Form S-4 - Registration of securities, business combinations:
11/07/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy